ANI Pharmaceuticals (ANIP)
(Delayed Data from NSDQ)
$64.95 USD
-0.48 (-0.73%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $64.94 -0.01 (-0.02%) 7:58 PM ET
1-Strong Buy of 5 1
C Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$64.95 USD
-0.48 (-0.73%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $64.94 -0.01 (-0.02%) 7:58 PM ET
1-Strong Buy of 5 1
C Value B Growth D Momentum B VGM
Zacks News
Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales
by Zacks Equity Research
Merck (MRK) beats first-quarter estimates for earnings and sales. The company raises its EPS range for 2024. Stock rises in pre-market.
BioMarin (BMRN) Beats on Q1 Earnings, Voxzogo Drives Sales
by Zacks Equity Research
BioMarin's (BMRN) earnings beat estimates in the first quarter of 2024, while revenues slightly miss the mark. The company maintains revenue guidance for 2024.
Bristol-Myers (BMY) Q1 Loss Narrower Than Expected, Sales Beat
by Zacks Equity Research
Bristol-Myers' (BMY) first-quarter 2024 loss is narrower than estimated. Sales surpass the consensus mark on the back of Eliquis, Reblozyl and Opdualag's encouraging performance. However, Opdivo sales disappoint.
Biogen (BIIB) Q1 Earnings Beat, Stock Up on Alzheimer Drug Uptake
by Zacks Equity Research
Biogen's (BIIB) first-quarter earnings beat estimates but sales miss the mark. While sales of key drugs like Tecfidera, Tysabri & Spinraza declined, the company's cost-saving efforts show promise.
Corcept (CORT) Posts Positive Data From Cushing's Syndrome Study
by Zacks Equity Research
Corcept (CORT) reports positive data from the open-label portion of the phase III GRACE study evaluating relacorilant for treating patients with Cushing's syndrome.
Sanofi (SNY) Rilzabrutinib Shows Benefit in Blood Disorder Study
by Zacks Equity Research
Sanofi's (SNY) BTK inhibitor, rilzabrutinib, demonstrates durable platelet response in the phase III LUNA 3 study in adult patients with immune thrombocytopenia.
Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition?
by Zacks Equity Research
Alkermes (ALKS) expects its set of proprietary products, Vivitrol, Aristada and Lybalvi, to generate incremental sales and combat stiff competition in 2024.
Roche (RHHBY) Alecensa Wins FDA Nod for Label Expansion
by Zacks Equity Research
Roche (RHHBY) has won FDA approval for Alecensa as an adjuvant treatment, following tumor resection for patients with ALK-positive non-small cell lung cancer.
Sage (SAGE) Down 20% on Parkinson's Study Missing Primary Goal
by Zacks Equity Research
Data from a mid-stage study show that Sage's (SAGE) experimental oral drug failed to show a statistically significant difference in treating patients with Parkinson's disease compared with a placebo.
Vanda (VNDA) Rejects Takeover Interest From Future Pak, Stock Up
by Zacks Equity Research
Vanda's (VNDA) board of directors unanimously rejects takeover proposals from Future Pak to acquire all outstanding shares of Vanda. Shares rise on the news.
GSK Announces FDA Acceptance of New Meningococcal Jab BLA
by Zacks Equity Research
The approval of GSK's 5-in-1 meningococcal ABCWY vaccine candidate, MenABCWY, could provide the broadest meningococcal serogroup coverage and lead to simplified immunization.
Aptevo (APVO) Stock Plummets 79% in a Week: Here's Why
by Zacks Equity Research
Aptevo (APVO) plunges after it issues secondary shares, which are not only issued at a significant discount but also substantially dilute the existing shareholder base.
Marinus (MRNS) Down 83% on Lead Drug Falling Short in Seizure Study
by Zacks Equity Research
Interim results from a late-stage study show that Marinus' (MRNS) ganaxolone failed to meet the pre-specified stopping criteria in patients with refractory status epilepticus.
Corcept (CORT) Completes Enrollment in Phase II ALS Study
by Zacks Equity Research
The phase II DAZALS study is evaluating Corcept's (CORT) dazucorilant for treating patients with amyotrophic lateral sclerosis. Enrollment in the study is already complete.
Neumora (NMRA) Down on FDA Clinical Hold on Neurology Drug
by Zacks Equity Research
The FDA places a clinical hold on Neumora's (NMRA) phase I study evaluating NMRA-266 for some types of neuropsychiatric disorders. Shares of the company fall on the news.
J&J (JNJ) Q1 Earnings Beat Estimates, Sales Miss, MedTech Soft
by Zacks Equity Research
J&J (JNJ) beats estimates for first-quarter earnings but misses the same for sales. It tightens its sales and earnings growth expectations for 2024.
Novartis (NVS) Presents Positive Data on Rare Kidney Disease Drug
by Zacks Equity Research
Novartis (NVS) announces encouraging data on Fabhalta from a phase III study for the treatment for the treatment of immunoglobulin A nephropathy, a heterogeneous, progressive, rare kidney disease.
Enlivex (ENLV) Stock Plummets 51% in a Week: Here's Why
by Zacks Equity Research
Enlivex (ENLV) plunges after it shares mixed results from a mid-stage study evaluating its lead drug as a potential treatment for sepsis.
Janux (JANX) Rises Almost 50% in a Week on Buyout Rumors
by Zacks Equity Research
Janux (JANX) stock surges after some reports claim that the company is exploring opportunities for a potential sale following buyout offers from big pharma companies.
Why ANI (ANIP) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
AstraZeneca's (AZN) Fasenra Gets FDA Nod for Asthma in Kids
by Zacks Equity Research
The FDA approves AstraZeneca's (AZN) Fasenra as an add-on maintenance treatment for patients with severe asthma aged six to 11 years.
ANI Pharmaceuticals (ANIP) Stock Moves -0.13%: What You Should Know
by Zacks Equity Research
ANI Pharmaceuticals (ANIP) closed at $66.96 in the latest trading session, marking a -0.13% move from the prior day.
Moderna (MRNA) Up 6% on Upbeat Data From Cancer Jab Study
by Zacks Equity Research
Data from an early-stage study shows that treatment with Moderna's (MRNA) experimental cancer therapy achieved positive clinical response in patients with a specific type of head and neck cancer.
Lisata's (LSTA) LSTA1 Gets FDA Orphan Drug Tag for Osteosarcoma
by Zacks Equity Research
The FDA bestows an Orphan Drug designation to Lisata's (LSTA) lead investigational product candidate, LSTA1, for the treatment of osteosarcoma. Stock rises.
Syros (SYRS) Up on FDA Fast Track Tag for Tamibarotene in AML
by Zacks Equity Research
The FDA bestows a Fast Track Designation to Syros' (SYRS) pipeline candidate, tamibarotene, in combination with venetoclax and azacitidine to treat newly diagnosed acute myeloid leukemia. Stock rises.